The Impact of Empagliflozin on Obstructive Sleep Apnea, Cardiovascular, and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial
Neeland IJ, Eliasson B, Kasai T, Marx N, Zinman B, Inzucchi SE, Wanner C, Zwiener I, Wojeck BS, Yaggi HK, Johansen OE. The Impact of Empagliflozin on Obstructive Sleep Apnea, Cardiovascular, and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020, 43: 3007-3015. PMID: 33004464, PMCID: PMC7770278, DOI: 10.2337/dc20-1096.Peer-Reviewed Original ResearchConceptsObstructive sleep apneaRenal outcomesOSA statusSleep apneaNew-onset obstructive sleep apneaMultivariable-adjusted Cox regression modelsBaseline obstructive sleep apneaMajor adverse CV eventsEMPA-REG OUTCOME trialEMPA-REG OUTCOMEImpact of empagliflozinPlacebo-adjusted reductionsAdverse CV eventsEffect of empagliflozinHeart failure hospitalizationSystolic blood pressureCox regression modelStandard of careCV deathCV eventsCV outcomesEmpagliflozin treatmentEMPA-REGRenal eventsCV disease